It will carry warnings about increased risk of suicidal thoughts and we don’t know the cost yet. Not all HMOs cover obesity
either as they are not convinced of the long term use and effectiveness. I don’t know after some of what I hear about antidepressants today, if I were in need of losing weight, don’t know if I would trust some of these pills myself. We sure like to map obesity in the US and it’s not getting any better. BD
Obesity Just As Big As Ever In the US–More Failed Ineffective Models As Technology Is Not The Cure With, Many Proof of Concepts Not Working, Obesity Algorithms Are Not the Answer
(Reuters) - A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.
Made by Orexigen Therapeutics Inc, Contrave is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, designed to prevent drug dependence.
The company did not say when the pill would become available or how much it would cost.
Contrave joins Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, both approved in 2012, in the battle to be the treatment of choice and at least one analyst expects the new entrant's sales to top that of its rivals by 2016.
0 comments :
Post a Comment